You are viewing an incomplete version of our website. Please click to reload the website as full version.

VEGFR2 antibody (Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase)) (AA 1300-1367)

Details for Product anti-KDR Antibody No. ABIN250774, Supplier: Log in to see
Antigen
  • 6130401C07
  • CD309
  • fk52c05
  • flk
  • FLK-1
  • flk-1
  • Flk-1
  • FLK/KDR
  • Flk1
  • flk1
  • FLK1
  • flk1b
  • kdr
  • KDR
  • kdra
  • kdrb
  • Krd-1
  • Ly73
  • si:busm1-205d10.1
  • si:ch211-254j6.1
  • si:ch211-278f21.4
  • sVEGFR-2
  • VEGFR
  • Vegfr-2
  • vegfr-2
  • VEGFR-2
  • VEGFR2
  • vegfr2
  • vegfr4
  • vegr2
  • wu:fc31a09
  • wu:fk52c05
Alternatives
anti-Human VEGFR2 antibody for Immunohistochemistry (Frozen Sections)
Epitope
AA 1300-1367, C-Term, Native Form
79
52
50
37
24
24
20
18
18
17
17
14
14
13
13
12
12
10
9
8
7
6
6
6
6
5
5
5
4
4
4
3
3
3
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Hamster, Human
552
280
151
5
5
4
3
2
2
2
1
1
1
1
1
1
1
1
1
Host
Rabbit
485
120
54
4
2
2
1
Clonality
Polyclonal
Conjugate
This VEGFR2 antibody is un-conjugated
39
28
22
16
14
12
9
7
5
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
Application
Immunocytochemistry (ICC), Immunofluorescence (IF), Western Blotting (WB)
407
233
205
145
105
79
34
27
23
22
17
16
8
8
7
6
5
2
2
1
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen A synthetic peptide made to a C-terminal region of the mouse VEGF Receptor 2 protein (between residues 1300-1367). [Swiss-Prot# P35918]
Specificity This has only been shown to recognize the native form (180-190 kDa protein) of VEGFR-2, known as Flk-1/ KDR/ VEGFR 2 (Vascular Endothelial Growth Factor Receptor 2), though it was raised against the precursor form.
Cross-Reactivity (Details) Predicted to react with mouse based on 100% sequence homology.
Purification Immunogen affinity purified
Alternative Name CD309 / VEGFR-2 / Flk-1 (KDR Antibody Abstract)
Background Gene Symbol: KDR
Molecular Weight Theoretical MW: 150 kDa
UniProt P35918
Pathways RTK Signaling
Application Notes Western Blot 1 μg/mL, Immunocytochemistry/Immunofluorescence 1:10
Comment

The antibodies are intended for use in vitro experiments only. Our antibodies have not been tested nor are recommended for use in vivo.

Protocol Western blot protocol specific for VEGF Receptor 2 Antibody Western Blot Protocol
1. Perform SDS-PAGE (4-12 %) on samples to be analyzed.
. Transfer proteins to Nitrocellulose according to the instructions provided by the manufacturer of the transfer apparatus.
. Rinse membrane with dH2O and then stain the blot using ponceau S for 1-2 minutes to access the transfer of proteins onto the nitrocellulose membrane. Rinse the blot in water to remove excess stain and mark the lane locations and locations of molecular weight markers using a pencil.
. Rinse the blot in TBS for approximately 5 minutes.
. Block the membrane using 5 % non-fat dry milk + 1 % BSA in TBS overnight at 4 °C.
. Rinse the membrane in dH2O and then wash the membrane in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each.
. Dilute the rabbit anti-VEGFR2 primary antibody in blocking buffer and incubate 1 hour at room temperature.
. Rinse the membrane in dH2O and then wash the membrane in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each.
. Apply the diluted rabbit-IgG HRP-conjugated secondary antibody in blocking buffer (as per manufacturer's instructions) and incubate 1 hour at room temperature.
. Wash the blot in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each (this step can be repeated as required to reduce background).
. Apply the detection reagent of choice in accordance with the manufacturer's instructions (we used BioFX Super Plus ECL).Note: Tween-20 can be added to the blocking or antibody dilution buffer at a final concentration of 0.05-0.2 %, provided it does not interfere with antibody-antigen binding.
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer Tris-citrate/phosphate, pH 7-8
Buffer contains: 0.1 % Sodium Azide
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Do not freeze.
Storage 4 °C
Storage Comment Store at 4°C. Do not freeze.
Supplier Images
Western Blotting (WB) image for anti-VEGFR2 antibody (Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase)) (AA 1300-1367) (ABIN250774) Detection of VEGFR2 doublet in CSF-IR/VEGFR2 chimera transfected lysate using ABIN250...
Immunofluorescence (IF) image for anti-VEGFR2 antibody (Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase)) (AA 1300-1367) (ABIN250774) Immunocytochemistry/Immunofluorescence: VEGF R2/KDR/Flk-1 Antibody [ABIN250774] - VEG...
Product cited in: Lim, Yap, Lim, Goh, Ng: "Identification of autocrine growth factors secreted by CHO cells for applications in single-cell cloning media." in: Journal of proteome research, Vol. 12, Issue 7, pp. 3496-510, 2013 (PubMed). (Sample species: Hamster). Further details: Western Blotting

Roan, Fang, Chang, Hsu, Huang, Chiou, Tsai, Lam: "Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model." in: Journal of vascular surgery, Vol. 56, Issue 5, pp. 1381-9.e1, 2012 (PubMed). (Sample species: Rat (Rattus)). Further details: Flow Cytometry

Hu-Lowe, Zou, Grazzini, Hallin, Wickman, Amundson, Chen, Rewolinski, Yamazaki, Wu, McTigue, Murray, Kania, OConnor, Shalinsky, Bender: "Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 22, pp. 7272-83, 2008 (PubMed).

Takahashi, Hattori, Iwamatsu, Takizawa, Shibuya: "A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1." in: The Journal of biological chemistry, Vol. 279, Issue 44, pp. 46304-14, 2004 (PubMed).

Rahimi, Dayanir, Lashkari: "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells." in: The Journal of biological chemistry, Vol. 275, Issue 22, pp. 16986-92, 2000 (PubMed).

Background publications Gluzman-Poltorak, Cohen, Shibuya, Neufeld: "Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 18688-94, 2001 (PubMed).